Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
+4.60%
$0.35
100% positive prob.
5-Day Prediction
+44.18%
$0.49
100% positive prob.
20-Day Prediction
+42.40%
$0.48
95% positive prob.
| Quarter | Signal | 1D Return | 5D Return | 20D Return | Confidence | Actual 5D |
|---|---|---|---|---|---|---|
| Q3 2026 | BUY | +4.60% | +44.18% | +42.40% | 100.0% | Pending |
| Q2 2026 | SELL | +0.80% | -5.24% | -30.24% | 100.0% | Pending |
| Q1 2026 | BUY | +4.87% | +65.85% | +53.99% | 100.0% | +0.00% |
| Q3 2025 | SELL | +2.88% | -3.90% | -37.66% | 100.0% | -1.59% |
SEC 8-K filings with transcript text
Oct 9, 2026 · 100% conf.
1D
+4.60%
$0.35
5D
+44.18%
$0.49
20D
+42.40%
$0.48
2 cosm_ex991.htm
cosm_ex991.htm
Cosmos Health Reports Record Preliminary Nine-Month Revenue of $54.3 Million, Up 19% Year Over Year; Delivers Record Q3 Revenue of $17.4 Million and Reaffirms 2026 Revenue Outlook of Over $90 Million
●
Record nine-month revenue of approximately $54.3 million — up 19%, or $8.7 million, from $45.6 million in the same period of 2025
●
Nine-month 2026 revenue nearly matches the whole of 2024 — when full-year revenue was $54.4 million — and represents 83% of record full-year 2025 revenue of $65.3 million
●
Record third-quarter revenue of approximately $17.4 million — exceeding the previous Q3 record of $17.1 million set in 2025, and up 40% on Q3 2024
●
Every quarter of 2026 has set a record for its period — Q1, Q2 and Q3 each exceeded the highest revenue previously reported for that quarter
●
Growth across all core segments — contract manufacturing, pharmaceutical distribution and proprietary brands, with accelerating sales momentum in the United States
●
2026 revenue outlook reaffirmed — the Company continues to expect full-year revenue to surpass $90 million, with the fourth quarter expected to be the strongest in its history
1
CHICAGO, IL / ACCESS Newswire / October 7, 2026 / Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ: COSM), a diversified, vertically integrated global healthcare group, today announced preliminary revenue of approximately $54.3 million for the nine months ended September 30, 2026 — a Company record and an increase of 19%, or $8.7 million, over the $45.6 million reported for the same period of 2025. Preliminary revenue for the third quarter was approximately $17.4 million, the highest third quarter in the Company’s history. The Company also reaffirmed its expectation that full-year 2026 revenue will surpass $90 million.
Nine Months That Nearly Equal a Full Year
In nine months, Cosmos Health has generated approximately the same revenue it reported for the whole of 2024, when full-year revenue was $54.4 million, and 83% of the record $65.3 million reported for the whole of 2025. Measured against the first nine months of 2024, revenue is up 35%.
Record Revenue in Every Quarter of 2026
First, second and third-quarter revenue each exceeded the highest revenue the Company had previously reported for that quarter. The third quarter was achieved against the most demanding comparison of the three.
Third-quarter revenue of approximately $17.4 million compares with $17.1 million in the third quarter of 2025 — which was, at the time, the highest quarterly revenue the Company had ever reported, and itself represented growth of 38%. Against that record base, third-quarter revenue increased again. Measured over two years, third-quarter revenue is up 40% from $12.4 million in the third quarter of 2024.
2
2024
2025
Third quarter
+2%
+40%
Nine months to September 30
+19%
+35%
Full year
Over $90M (outlook)
+38%
+65%
2026 third-quarter and nine-month figures are preliminary and unaudited. Full-year 2026 reflects the Company’s outlook, not results. Percentages are calculated on rounded figures.
Growth Across the Company’s Core Segments
The increase reflects growth across each of the Company’s core segments. Contract manufacturing at Cana Laboratories reached a record production pipeline of more than 32.7 million units, and pharmaceutical distribution at CosmoFarm delivered record volumes across a network of more than 1,500 pharmacies that continues to expand. The Company’s proprietary brands — among others, Sky Premium Life, C-Scrub and C-Sept — grew in their established markets and entered new territories and channels globally, while sales momentum in the United States continued to build.
2026 Outlook Reaffirmed: Over $90 Million in Revenue
Cosmos Health reaffirms its previously announced expectation that revenue for full-year 2026 will surpass $90 million, which would represent growth of approximately 38% over 2025. The Company currently expects the fourth quarter of 2026 to be the strongest quarter in its history, supported by contract manufacturing orders, seasonal strength in distribution and accelerating sales in the United States.
Greg Siokas, CEO of Cosmos Health, stated: “In nine months we have delivered approximately what took us a full year in 2024. Revenue of approximately $54.3 million is 19% ahead of last year, and it comes after a record first quarter, a record second quarter and now a record third quarter — the third achieved against the most demanding comparison in the Company’s history.
“That growth is coming from every part of the business. Our contract manufacturing pipeline is at a record level, our distribution volumes are the highest we have recorded, and our proprietary brands are growing in their established markets while reaching new ones.
“The infrastr
Aug 20, 2026 · 100% conf.
1D
+0.80%
$0.21
Act: +4.19%
5D
-5.24%
$0.20
20D
-30.24%
$0.15
Transcript text not available. View on SEC.gov →
May 22, 2026 · 100% conf.
1D
+4.87%
$0.26
Act: +3.96%
5D
+65.85%
$0.42
Act: +0.00%
20D
+53.99%
$0.39
2 cosm_ex991.htm
cosm_ex991.htm
Cosmos Health Reports Q1 2026 Results: Revenue Up 31% to $17.9M, New Q1 Record; Total Liabilities Reduced by $4.5M; Stockholders' Equity Up 7.6%; Cash of $2.2M; Record Momentum Continues into Q2 with U.S. Expansion Underway
· Record Q1 revenue of $17.9M, up 31% from $13.71 million in Q1 2025, reflecting strength across all core segments
· Total liabilities decreased by $4.5M, or 9.6%, driven by a substantial reduction in convertible note and credit facility balances
· Stockholders' equity increased by $1.4M, or 7.6%, with the liabilities-to-assets ratio improving by 370 basis points
· Adjusted EBITDA near breakeven as increased revenue was offset by strategic investments to support global growth
· Record momentum continues into Q2 2026 with U.S. expansion actively underway
CHICAGO, IL / ACCESS Newswire / May 21, 2026 / Cosmos Health Inc. (“Cosmos Health” or the “Company”)(NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today reported financial results for the first quarter ended March 31, 2026.
First Quarter 2026 Financial Highlights
Income Statement
Cosmos Health delivered the highest Q1 revenue in Company history with continued progress toward adjusted profitability, reflecting broad-based commercial strength — over 75 new pharmacies added at CosmoFarm, growing Sky Premium Life order activity across multiple markets, and expanded contract manufacturing agreements at Cana Laboratories.
·
Revenue was $17.93 million, an increase of 30.7% from $13.71 million in Q1 2025, reflecting strong sales momentum across all core divisions.
○
Adjusted revenue was $18.40 million, up 34.2% year-over-year, reflecting a $470,601 sales discount reversal.
·
Gross profit was $1.38 million in Q1 2026, compared to $2.05 million in Q1 2025, reflecting a revenue mix shift toward wholesale distribution activity at CosmoFarm, compounded by the aforementioned sales discount adjustment.
○
Adjusted gross profit was $1.85 million, reflecting the sales discount reversal applied to revenue.
·
Total operating expenses increased to $3.57 million in Q1 2026, compared to $2.88 million in Q1 2025, reflecting strategic investments in personnel, infrastructure, technology, and AI-driven efficiencies to support global growth initiatives.
1
·
Net income (loss) was ($2.81 million) in Q1 2026, compared to ($0.82 million) in Q1 2025. The increase is driven principally by $1.15 million of non-cash, non-operational items:
○
$390,350 in non-cash interest on convertible facilities
○
$442,439 in digital asset mark-to-market losses
○
$313,157 in foreign currency translation losses
·
Adjusted EBITDA was ($229,596) in Q1 2026, near breakeven, as increased revenue was offset by higher expenses reflecting the Company's ongoing investments in global growth initiatives.
·
Adjusted Net Income (Loss) was ($996,502), driven by $766,906 in interest expense incurred in support of the Company's growth investments.
Balance Sheet
Cosmos Health continued to improve its balance sheet in Q1 2026, with active debt reduction and working capital optimization driving an improvement in the liabilities-to-assets ratio to 68.2% from 71.9% at year-end 2025.
·
Total assets were $62.37 million as of March 31, 2026, compared to $65.48 million at December 31, 2025, reflecting a diversified asset base with solid liquidity, a strong inventory position, and a significant real estate and intellectual property portfolio.
○
Liquid assets totaled $4.3 million, comprising cash and cash equivalents of $2.2 million as well as digital assets and marketable securities of $2.1 million.
·
Total liabilities decreased by $4.51 million, or 9.6%, to $42.54 million as of March 31, 2026, from $47.05 million at December 31, 2025, driven by a substantial reduction in convertible note and credit facility balances.
·
Total stockholders' equity increased by $1.40 million, or 7.6%, to $19.83 million as of March 31, 2026, up from $18.42 million at December 31, 2025.
Management Commentary
Greg Siokas, CEO of Cosmos Health, stated: “Q1 2026 was a record Q1 for Cosmos Health, with revenue of $17.93 million, up 31% year-over-year and 34% on an adjusted basis, reflecting broad-based commercial momentum across every major division — record distribution volumes at CosmoFarm, continued global expansion of Sky Premium Life, and new contract manufacturing agreements at Cana Laboratories.
This momentum is continuing into Q2 2026, and we are focused on sustaining it well beyond this year. We believe Cosmos Health is entering a new phase of growth, driven by strategic investments across our organization — in personnel, facilities, infrastructure, technology, and AI-driven efficiencies — to support our global expansion plans, strengthen our R&D pipeline, and build the foundation for long-term sustainable value creation. A key pillar of this growth is our entry into the lucrative U.S. nu
This page provides Cosmos Health Inc. (COSM) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on COSM's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.